News | May 29, 2007

Sickest Heart Patients May Not Get Treatments They Need

May 30, 2007 -- The Canadian Press reports this week that people in the greatest need of cardiac medications and interventions are less likely than moderately ill patients to get the full range of heart drugs and procedures, and it may be because they fail the "eyeball" test.

Two American cardiologists have suggested that doctors may view these patients, the sickest of the sick, as too ill to benefit from invasive treatments like catheterization or too depressed or unwell to deal with the hassle of more medication in what is likely already a multi-pill daily regime.

Dr. John Spertus of the University of Missouri, Kansas City and Dr. Mark Furman of the University of Massachusetts Medical School express their views in an editorial in the "Archives of Internal Medicine."

Their editorial accompanies two studies by Canadian research teams that found that sicker patients were less likely to be getting an important cholesterol lowering drug called a statin or to undergo cardiac catheterization.

The studies add support to what's called the treatment-risk paradox, a phenomenon first described by researchers at Toronto's Institute for Clinical Evaluative Studies.

They reported in 2004 that patients who would benefit most from cardiac interventions were least likely to be getting them.


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now